Achieving Precision Medicine in Psoriatic Arthritis: Novel Treatment Strategies and Trial Designs
Related Experiment Video
Updated: Sep 14, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Shannon Gunawardana1, William Tillett2, Laura C Coates1
1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford, OX3 7LD, UK.
Abstract:
Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthropathy with phenotypic, pathogenetic, and radiologic heterogeneity. Over the last 20 years, a wide range of biologic disease modifying anti-rheumatic drugs (bDMARDs) have been licensed for the treatment of PsA. Precision medicine aims to choose the right treatment for the right patient at the right time. Current clinical trials are using biomarker-targeted treatment approaches to guide bDMARD selection. There is an ongoing debate as to whether a blood or tissue biomarker is the superior approach. Master protocol trials, including basket and umbrella trials, could revolutionize testing novel therapeutic strategies in PsA and spondyloarthropathies.
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Peripheral Artery Disease III: Interprofessional Care
Drug Therapy
Antianxiety Medications

